Unique skills and experiences enable us to successfully integrate life sciences and data sciences

Management Team:
Aditya is the inventor of HDPCR, ChromaCode's core technology. Previously, he was a researcher at Google[x], where he worked on novel medical imaging methods. He has expertise in thermal engineering, digital signal processing, nano-scale electronics, low-power circuit design for implantable sensors, DNA sequencing structures and techniques, and PCR devices and applications. Additionally, he has an appointment as a Visiting Associate (Visiting Faculty) at Caltech, and has over 50 papers and publications. He was the recipient of the Caltech Innovation Initiative (CI2) award and the Demetriades-Tsafka-Kokkalis thesis prize. Aditya completed his education at Caltech (BS, MS, PhD) with Dr. Axel Scherer and Dr. Tom Tombrello.
Alex is a life sciences executive with over 25 years experience leading strategic initiatives that have transformed small companies and enabled large companies to penetrate new markets. Most recently, he was the Senior Vice President of Strategic Initiatives at Illumina, Inc. where his responsibilities included working with national governments and large institutions to develop precision medicine programs for healthcare systems. Previously he led the team that built Illumina’s cloud-based sequencing informatics platform, BaseSpace, now the world’s largest genomic database. Alex joined Illumina in 2010 when the company acquired Helixis, a molecular diagnostics company that he led as CEO after co-founding with Caltech Professor Axel Scherer and Nobel Laureate David Baltimore. Alex was previously the founder and CEO of Luxtera, the leading provider of silicon photonic cloud infrastructure. He began his career as a researcher at AT&T Bell Labs and has been awarded over 40 patents covering a range of inventions including the camera and fingerprint CMOS chip technologies widely used in today’s smartphones. He holds a Ph.D. from the University of Adelaide, Australia, and an MBA from Columbia University in New York.
Brett has over twenty years of experience in finance, corporate management, and human resources. He has worked in a broad range of industries and company sizes. His passion is helping companies with ground-breaking technology strategically expand their teams. At Luxtera, a pioneer in optics and electronic integration, he helped shape the company’s evolution from early research and development to initial revenue. Before joining ChromaCode he was the VP of Finance for Genalyte, Inc. a sample-to-answer clinical diagnostics device manufacturer, where he helped manage the growth of the company from 35 to 90 employees. He has BS in Electrical Engineering from the University of Colorado and MBA from the University of California, Irvine.
Chris is an experienced engineer and manager in the life sciences industry focused on data science, product engineering and process development. Most recently, he was an engineering manager at Illumina, leading the development of processes for consumables manufacturing across several major platforms, including the HiSeqX nanopatterned flowcell which enabled the $1000 genome. He also led development of an analytics platform linking field sequencing data to the consumables manufacturing data stream, allowing real-time monitoring of global product quality. Chris was the recipient of a Fulbright Scholarship to develop novel biocompatible materials at the University of Sydney as well as a Siebel Scholarship for his doctoral work on multi-scale computational modeling of neuroglial networks. He holds a B.S. Electrical Engineering and a B.S. Physics from Lehigh University, and a Ph.D. in Bioengineering from UC San Diego. He is a Six Sigma Black Belt and Certified Biomedical Auditor through the American Society for Quality.
Greg has over 20 years of management experience in the molecular diagnostics and nucleic acids research fields. He spent 9 years at Luminex, when the company grew revenues from $30 million to over $200 million. He held multiple roles including VP of Sales and Marketing, where he was responsible for global commercial operations, and VP/GM of Biosciences, where was responsible for developing novel instrument and assay products for gene expression, microRNA, newborn screening and Alzheimer's disease. Prior to Luminex, Greg served in various commercial leadership roles at Nanogen, Chiron Diagnostics and Bio-Rad. He has a bachelors degree in molecular, cellular and developmental biology from the University of Colorado and dual masters degrees in business and healthcare administration from the University of Minnesota.
Karen has over 20 years industry experience in leadership capacities spanning research, product development, clinical affairs, regulatory, quality assurance, and operations. Her core expertise lies in the development and deployment of Molecular Diagnostic products. Most recently as Director of Programs for GSSHealth she was responsible for establishing programs for quality improvement in clinical laboratories serving HIV patients in West Africa, and prior to that was Associate Director of Development for the Novartis Dx Infectious Diseases Franchise. Karen earned her PhD in Biochemistry at the Johns Hopkins University School of Public Health and her Bachelor of Science in Biochemistry at the University of California Davis.
Lynne has over 35 years’ experience in the healthcare industry in the areas of finance and business development. She is currently a CFO consultant for start-up pharmaceutical and medical device companies and has worked with 35 start-up companies over the last 15 years. Prior to that, she was with Baxter Healthcare Corporation for 19 years. Her positions at Baxter included Vice President of Business Development for the Cardiopulmonary Business of the CardioVascular Group and Vice President of Finance for the Cardiopulmonary Business. Ms. Rollins received her B.S. degree from California State University, Northridge and her MBA from Pepperdine University.
Patricia has 30 years of diagnostic and life science industry experience spanning research, product development, clinical affairs, regulatory affairs and commercial operations. Patricia has worked for many of the top industry leaders including Abbott, Luminex, Hologic and Qiagen, holding positions of increased leadership responsibility. Patricia has extensive commercial experience in molecular diagnostics and was a key member of one of the first product launches in the space, Abbott’s LCx Chlamydia. Patricia received her Bachelor of Science degree in Medical Microbiology from The University of Wisconsin-Madison.
Paul has over twenty years experience in software development and scientific research. He has directed multiple teams developing industry-leading scientific software and has published in various areas including Molecular Modeling, Bioinformatics, Genetics and Molecular Evolution. Before joining ChromaCode, Paul led the BaseSpace development team at Illumina, where he oversaw commercialization and clinical transformation of the cloud genomics platform. Prior to this he directed the Life Sciences R&D team at BioVia (Accelrys), where he led development of Bioinformatics, Molecular Modeling and Cheminformatics software. He began his career as a faculty member at University of Basel, Switzerland, where his research focused on Molecular Evolution. Paul received a PhD in Molecular Genetics from the Liverpool School of Tropical Medicine and a BSc in Genetics from University College London.
Board of Directors:
Aditya is the inventor of HDPCR, ChromaCode's core technology. Previously, he was a researcher at Google[x], where he worked on novel medical imaging methods. He has expertise in thermal engineering, digital signal processing, nano-scale electronics, low-power circuit design for implantable sensors, DNA sequencing structures and techniques, and PCR devices and applications. Additionally, he has an appointment as a Visiting Associate (Visiting Faculty) at Caltech, and has over 50 papers and publications. He was the recipient of the Caltech Innovation Initiative (CI2) award and the Demetriades-Tsafka-Kokkalis thesis prize. Aditya completed his education at Caltech (BS, MS, PhD) with Dr. Axel Scherer and Dr. Tom Tombrello.
Alex is a life sciences executive with over 25 years experience leading strategic initiatives that have transformed small companies and enabled large companies to penetrate new markets. Most recently, he was the Senior Vice President of Strategic Initiatives at Illumina, Inc. where his responsibilities included working with national governments and large institutions to develop precision medicine programs for healthcare systems. Previously he led the team that built Illumina’s cloud-based sequencing informatics platform, BaseSpace, now the world’s largest genomic database. Alex joined Illumina in 2010 when the company acquired Helixis, a molecular diagnostics company that he led as CEO after co-founding with Caltech Professor Axel Scherer and Nobel Laureate David Baltimore. Alex was previously the founder and CEO of Luxtera, the leading provider of silicon photonic cloud infrastructure. He began his career as a researcher at AT&T Bell Labs and has been awarded over 40 patents covering a range of inventions including the camera and fingerprint CMOS chip technologies widely used in today’s smartphones. He holds a Ph.D. from the University of Adelaide, Australia, and an MBA from Columbia University in New York.
Greg has over 20 years of management experience in the molecular diagnostics and nucleic acids research fields. He spent 9 years at Luminex, when the company grew revenues from $30 million to over $200 million. He held multiple roles including VP of Sales and Marketing, where he was responsible for global commercial operations, and VP/GM of Biosciences, where was responsible for developing novel instrument and assay products for gene expression, microRNA, newborn screening and Alzheimer's disease. Prior to Luminex, Greg served in various commercial leadership roles at Nanogen, Chiron Diagnostics and Bio-Rad. He has a bachelors degree in molecular, cellular and developmental biology from the University of Colorado and dual masters degrees in business and healthcare administration from the University of Minnesota.
Jim has been a partner of the venture capital firm Domain and Associates since the firm’s founding in 1985. Jim has more than 40 years of experience with venture and emerging growth companies. He has been involved in the creation and successful development at the board level of more than 40 life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Cadence Pharmaceuticals, Dura Pharmaceuticals, GeneOhm Sciences, Molecular Dynamics, NuVasive, Pharmion and Volcano. Other current board memberships include Applied Proteomics, Astute Medical, aTyr Pharma, Clovis Oncology, CoDa Therapeutics, IntegenX, and NeuroPace. Jim also currently serves on the board of directors of the Prostate Cancer Foundation and the Sanford-Burnham Medical Research Institute and he is on the advisory boards of the Department of Molecular Biology at Princeton University, the USC Stevens Institute for Innovation, and the Caltech Division of Chemistry and Chemical Engineering.

Prior to Domain, Jim was a former managing director of Rothschild Inc., where he was directly involved at a senior level with Rothschild/New Court venture capital activities. Previous to that, he was associated with F.S. Smithers and Co. and White, Weld and Co., two investment banking firms actively involved with new ventures and emerging growth companies. Jim was an engineering manager with RCA Corporation, during which time he received the David Sarnoff Fellowship. He received his BSE from Princeton University and his MSE and Ph.D. in electrical engineering from the University of Pennsylvania.
Justin joined NEA in 2006 and is a Partner on the healthcare team. He focuses on medical device, healthcare technology, and biopharmaceutical company investments. He serves as a director of Advanced Cardiac Therapeutics, Cartiva, FIRE1, Intact Vascular, Personal Genome Diagnostics, PhaseBio Pharmaceuticals, Relievant Medsystems, Senseonics (NYSE: SENS), VertiFlex, Vesper Medical, and VytronUS. Justin’s past board memberships and investments include CV Ingenuity (acquired by Covidien), Nevro (NYSE: NVRO), Topera (acquired by Abbott), TriVascular (NASDAQ: TRIV), and Ulthera (acquired by Merz). He is also a member of the advisory boards for the National Venture Capital Association’s Medical Industry Group and its Medical Innovation and Competitiveness Coalition (MedIC), as well as a member of AdvaMed's Business Development Committee.

Prior to NEA, Justin worked for the Duke University Health System—reporting directly to the hospital CEO on health system strategy, finance and clinical service unit operations—as Duke built one of the nation's first and largest healthcare integrated delivery systems. Justin concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School. He has also served as a member of the Board of Trustees of Duke University, where he earned his AB in Economics and his BS in Biological Anthropology and Anatomy.
Corporate Advisors:
Andrea is the Chair of the Division of Molecular Diagnostics in the Department of Pathology at the Virginia Commonwealth University Health System. She is also the director of the Molecular Diagnostics Laboratory at the VCU Health System.

Andrea is an internationally recognized expert in the field of molecular diagnostics in the area of genetics, oncology, personalized medicine, pharmacogenetics and infectious diseases in transplantation. In addition, she has played a major role in shaping national policy regarding the practice, reimbursement and guideline development for molecular diagnostics and molecular genetic testing.

Andrea has also served as President of the Association for Molecular Pathology. More recently, she served on the Department of Justice and National Institute of Standard and Technology National Commission on Forensic Sciences. She was the recipient of the AMP Leadership Award for her major contributions to the field. She is a member of the Molecular Biology Education Committee for the International Federation of Clinical Chemistry (IFCC) where she has participated over the last 4 years in developing educational standards and hands on workshops on genetic testing for developing countries.

Andrea received her PhD degree from the George Washington University in Washington DC in 1994 and a master’s degree in Clinical Biochemistry from the National University of Cordoba, Argentina and she is board certified by the American Board of Bioanalysis as High Complexity Laboratory Director and Clinical Consultant.
Dr. David Hillyard is Director of Molecular Infectious Disease Testing at ARUP Laboratories, a leading institution for esoteric laboratory testing, and a Professor of Pathology at the University of Utah. Dr. Hillyard is a renowned expert in infectious disease test development and utilization and has authored over 100 papers in the field. In 2014 he was inducted into the National Academy of Inventors. He currently serves as the Chair of the Infectious Disease Subdivision for the Association of Molecular Pathology. Dr. Hillyard received his MD from the Columbia University College of Physicians and Surgeons, and completed his training in anatomic and clinical pathology, with fellowships in medical microbiology and microbial genetics.
Greg is the Director of the Laboratory for Clinical Genomics and Advanced Technology (CGAT) at the Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center in Lebanon, NH and a Professor of Pathology at the Geisel School of Medicine at Dartmouth in Hanover, NH. He was the inaugural director of the molecular pathology laboratory at Hartford Hospital in Hartford, CT before going to Dartmouth. His area of expertise is in clinical molecular diagnostic applications. His research interests are in the pathogenesis of human cancers, personalized medicine and disruptive technologies. He has authored/edited eight textbooks in the field of molecular pathology, published more than 185 peer reviewed manuscripts, and has been an invited speaker at both national and international meetings.

Greg has served on numerous committees of the AACC, ASIP, and AMP where he is a past President and currently serves on the FASEB board of directors. He is on the editorial board of 9 journals including Clinical Chemistry, Clinical Chemistry and Laboratory Medicine and the Journal of Molecular Diagnostics. He also serves on numerous corporate scientific advisory boards. He received his Ph.D. in Pathology from the University of Medicine and Dentistry of New Jersey and completed his postdoctoral training in molecular oncology and clinical chemistry/molecular pathology in the Department of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill.
Michael has been an Engineering Director at Google since 2002 where his responsibilities have ranged from managing large engineering teams responsible for most of Google’s revenue, to overseeing critical internal software infrastructure projects. Michael currently leads a Google Research team that he founded, whose primary aim is to bring Google’s expertise in machine intelligence and machine perception to bear on fundamental scientific research.

Previously, Michael held several leadership roles at companies focused on large-scale computing and machine learning including being an advisor to Khosla Ventures, working primarily in the areas of data science and biology; CTO of Gamechange Inc., an early stage venture fund; Excite where he was responsible for web crawl and e-commerce engineering initiatives; NeXT where he worked on distributed computing systems; and Verity, a pioneering information retrieval company, where he was part of the core text retrieval group. Michael graduated with SB and SM degrees in Computer Science and Engineering from MIT.
Yaser is a Professor of Electrical Engineering and Computer Science at the California Institute of Technology, and Chairman of Machine Learning Consultants LLC. His main fields of expertise are machine learning and computational finance. He is the author of Amazon's machine learning bestseller Learning from Data. His MOOC on machine learning has attracted more than two million views.

He received the Clauser Prize for the most original doctoral thesis at Caltech. He received the ASCIT Teaching Awards in 1986, 1989 and 1991, the GSC Teaching Awards in 1995 and 2002, and the Richard P. Feynman prize for excellence in teaching in 1996. He was the founding Program Chairman of the annual conference on Neural Information Processing Systems (NIPS), and a founding member of the IEEE Neural Networks Council. He chaired the second and fourth international conferences on Neural Networks in the Capital Markets (NNCM-94 and NNCM-96), and the sixth international conference on Computational Finance (CF-99). In 2005, the Hertz Foundation established a perpetual graduate fellowship named in his honor.

Yaser currently serves as an advisor and technical consultant on machine learning for several companies, including Citibank for 9 years. He has numerous technical publications including 3 articles in Scientific American, as well as several keynote lectures at international conferences.

Contact Us

Phone

(442) 244-4369

Address

ChromaCode, Inc., 2330 Faraday Ave., Suite 100 Carlsbad, CA 92008 USA

E-Mail

info@chromacode.com hr@chromacode.com